SGLT2 inhibitors, such as empagliflozin, with a half-life of 12.4 hours, are expected to clear the bloodstream in about 48 hours, yet this case suggests an association with EDKA both during use and after drug cessation. This delayed presentation highlights additional risk considerations associated...
Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D) - An Observational Study (PAUSE) (1884-LB) Rybelsus®(once-daily oral ...
Sodium glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of glucose-lowering drugs in the management of type 2 diabetes mellitus (T2DM). In... LH Chen,PS Leung - 《Diabetes Obesity & Metabolism》 被引量: 89发表: 2013年 Effect of motilin on gastric emptying in patients wi...
Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as an important approach for the treatment of heart failure in patients with or with...
The use of SGLT2 inhibitors has been increasing dramatically in the last few years. Therefore, their adverse effects and complications have also been increasing. Herein, this report describes a 73-year-old man with type 2 DM treated with empagliflozin presenting with asymptomatic bacteriu...
EUGLYCEMIC DIABETIC KETOACIDOSIS WITH SGLT2 INHIBITOR USE IN A PATIENT ON THE ATKINS DIET: A UNIQUE PRESENTATION OF A KNOWN SIDE EFFECTThe Food and Drug Administration has approved the use of sodiumglucose cotransporter 2 (SGLT2) inhibitors for use in Type II diabetics. These are a relatively ...
Fifth, since the operators’ names were not recorded in the electronic case report forms (eCRFs), the impact of operator’s experience on the clinical outcome [46] after PCI cannot be assessed. Sixth, sodium-glucose contransporter 2 inhibitor (SGLT-2) drugs were not available at the time ...
Eur J Clin Pharmacol. 2014:;70:1149- 1158.Carlson C, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Safety DOI:10.1080/147403338.2016.1216100Marile L Santamarina MS...
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS However, some cases had an atypical presentation with a lower-than-expected degree of hyperglycemia. Lower-than-expected hyperglycemia, ...
OJ-372 Molecular Angioscopy of Lysophosphatidylcholine in the Human Atherosclerotic Coronary Plaques(Atherosclerosis, clinical-5 (H) OJ62,Oral Presentation... Uchida,Yasumi,Uchida,... - 《Circulation Journal Official Journal of the Japanese Circulation Society》...